China will reap the benefits of an antibiotic backed by U.S. taxpayers after the company that developed the drug auctioned off its rights amid bankruptcy.
Such deals may be on the horizon as other antibiotic manufacturers struggle to stay afloat.
San-Francisco based Achaogen Inc., which filed for bankruptcy in April, recently agreed to sell exclusive Chinese rights for its antibiotic Zemdri to Chinese drug maker QiLu Antibiotics Pharmaceutical Co. The drug, used to treat urinary tract infections, was supported by $124.4 million from the Department of Health and Human Services as part of a biodefense program incentivizing the creation of ...